🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

249 results for “ISTA” Clear

  1. Abiraterone Acetate

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  2. Acetohydroxamic Acid

    China SXT Pharmaceuticals

    Multidrug-Resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  3. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  4. B013

    BRIGHT MINDS BIOSCIENCES INC.

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  5. CARBOPLATIN , ETOPOSIDE , ENZALUTAMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, MK-7684A, DOCETAXEL , Belzutifan, Lenvatinib, Lenvatinib, PREDNISONE , ABIRATERONE , DEXAMETHASONE , Olaparib

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  6. CYSTAGON 50 mg hard capsules

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Pulmonary Tuberculosis

    phase 2 small molecule active

    1 trial

  7. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  8. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb / Pfizer EEIG

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  9. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb / Pfizer EEIG

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  10. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Ophthalmics Europe

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  11. DZR123, DZR123, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  12. Dantrolene sodium semiheptahydrate, SODIUM CHLORIDE, VISTABEL 4 Allergan-Einheiten/0,1 ml Pulver zur Herstellung einer Injektionslösung, FTP-002/FTP-501 combination

    Pharma Mar S.A.

    glabellar lines.

    phase 2 small molecule active

    1 trial

  13. Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Dexamethason 4 mg JENAPHARM®, teclistamab, teclistamab, Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 2 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Pomalidomide, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Im

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  14. EPI-7386, Xtandi - 40 mg soft capsules

    Pharma Mar S.A.

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  15. Enzalutamide 40mg

    United Therapeutics Europe Ltd

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  16. Etrumadenant

    Arcus Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule completed

    1 trial

  17. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  18. Fasedienol Nasal Spray - Placebo Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 2 small molecule active

    1 trial

  19. INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

    Roche Registration Limited

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  20. INAVOLISIB, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, Inavolisib placebo, FULVESTRANT

    Roche Registration Limited

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  21. ISIS EIF4E Rx

    IONIS PHARMACEUTICALS INC

    Castrate-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  22. Inlyta 1 mg film-coated tablets, Inlyta 3 mg film-coated tablets, CELLTOP 50 mg, capsule molle, ETOPOSIDE VIATRIS 20 mg/ml, solution à diluer pour perfusion

    ISTA Pharma Limited

    Ependymoma, Medulloblastoma

    phase 2 small molecule active

    1 trial

  23. Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.

    China SXT Pharmaceuticals

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  24. Irofulven

    Allarity Therapeutics

    Metastatic Castration-Resistant Prostate Cancer Patients

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources